Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120807 · ClinicalTrials.gov registry record · Phase 1
Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
A Phase 1 study of Stage IV Lung Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT02120807 is a Phase 1 study of Stage IV Lung Adenocarcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants. The trial reports 6 study locations across 2 states.
The verdict
NCT02120807, a Phase 1 study of Stage IV Lung Adenocarcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to test the safety of certolizumab when it is given with the chemotherapy drugs cisplatin and pemetrexed. Cisplatin and pemetrexed are two chemotherapy drugs used in the treatment of lung cancer. The investigators want to find out what effects, good and/or bad, certolizumab has on the patient and lung cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG pemetrexed
- DRUG Certolizumab
Study Locations (6)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering West Harrison - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering at Mercy Medical Center - Rockville Centre
- Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center - Sleepy Hollow
New Jersey
- Memorial Sloan Kettering at Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-04-15 |
| Est. Completion | 2023-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02120807
The ClinicalTrials.gov registry entry for NCT02120807 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage IV Lung Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.
NCT02120807 reports 6 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02120807 about?
NCT02120807 is a clinical study titled "Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas". The purpose of this study is to test the safety of certolizumab when it is given with the chemotherapy drugs cisplatin and pemetrexed. Cisplatin and pemetrexed are two chemotherapy drugs used in the treatment of lung cancer. The investigators want to find out what effects, good and/or bad, certolizu...
What is the current status of trial NCT02120807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-04-15. Estimated completion is 2023-01-24.
What conditions does trial NCT02120807 study?
This clinical trial studies the following conditions: Stage IV Lung Adenocarcinoma.
What interventions are being tested in trial NCT02120807?
The interventions under investigation include: cisplatin (DRUG), pemetrexed (DRUG), Certolizumab (DRUG).
Who is sponsoring clinical trial NCT02120807?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02120807 being conducted?
This trial has 6 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.